Lupin’s arm gets USFDA approval for norethindrone tablets

20 Sep 2011 Evaluate

Pharma major, Lupin’s subsidiary, Lupin Pharmaceuticals Inc. (LPI) has been granted final approval by the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) to market a generic version of Watson’s NOR-QD tablets. The company will commence shipping its norethindrone tablets, USP 0.35 mg shortly.

NOR-QD (norethindrone tablets, USP 0.35 mg) is a progestin-only oral contraceptive indicated for the prevention of pregnancy. Combined annual sales for NOR-QD and its generic equivalents were approximately $52 million for the twelve months ended June 2011 based on IMS Health sales data.

Recently, Lupin Pharmaceutical Inc (LPI) had been granted final approval by the US Food and Drug Administration (FDA) for the company’s Abbreviated New Drug Application (ANDA) to market a generic version of UCB’s Keppra XR tablets.

Lupin Share Price

2069.95 26.65 (1.30%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.